Skip to main content
. Author manuscript; available in PMC: 2021 Jul 1.
Published in final edited form as: Ann Biomed Eng. 2019 Nov 4;48(7):1864–1884. doi: 10.1007/s10439-019-02399-7

Table 1:

Therapeutic moieties available to inhibit Wnt, Hh, and Notch signaling.

Pathway Target Therapeutic Moiety
Wnt Extracellular ligands SFRP1
Frizzled receptor Wnt5a
Wnt-C59
Anti-Frizzled7 antibody
LRP 5/6 receptor iWnt peptide
β-catenin Niclosamide
IWR-1
KYA1797K
FH535
siCTNNB1
siBag-1
iCRT 3/14
PNU-74654
Gigantol
DANCR lncRNA
β-catenin and c-Myc miR-105
IWP-2
DK419
miR-200c
c-Myc c-Myc shRNA
GSK-3β Cromolyn
Pyrvinium pamoate
Wnt-1 siWnt-1
Adavivint
Wogonin
Hh Shh Robotnikinin
Anti-Shh 5E1 antibody
Anti-Shh MEDI-5304 antibody
Ptc1 Ant-Patched-1 antibody
Smo HhAntag
Cyclopamine
Vismodegib
DHCEO
SMANT
DY131
Itraconazole
ALLO-1/2
Compound 5
Jervine
Cur-61414
SANT 1–4
Saridegib
Sonidegib
TAK-441
BMS-833923
LEQ506
PF-04449913
LY2940680
Vitamin D3
BRD-6851
SEN450
MRT-83
Gli1 Quinacrine
GANT61
GANT58
Arcyriaflavin C
Physalins F
siGli1
Gli1/2 HPI1–4
Gli-DNA binding Anthothecol
Glabrescione B
Arsenic trioxide
Notch ADAM 10/17 INCB7839
INCB3619
INCB8765
KP457
GM6001
GI254023X
8C7 antibody
D1(A12) antibody
A9(B8) antibody
MEDI3622 antibody
ADAM10 prodomain
Rapamycin
MAML1 MAM peptide antagonist
SAHM1
Notch receptors Notch-1 shRNA
Soluble Notch1
Soluble DLL1
Soluble Jagged1
Genistein
Sulforaphane
Quercetin
Curcumin
Resveratrol
miR-34a
Anti-Notch-1–3 antibody
Jagged/Delta siJagged1 antibody
Anti-DLL1–4 antibodies
Nicastrin antibody
DAPT
MRK-560
MRK-003
PF-03084014
MK-0752
BMS-906024
DBZ (LY411575)
LY450139
RO4929097